BGLC
BioNexus Gene Lab Corp.
NASDAQ · Healthcare · Medical - Diagnostics & Research · MY
$1.41
−4.08%Margins
Gross margin
11.6%
EBITDA margin
-78.0%
EBIT margin
-82.8%
Net margin
-82.4%
FCF margin
-27.8%
-33.1%
Return on equity
-29.5%
Return on assets
-32.4%
Return on invested capital
0.21x
Asset turnover
-$842.4K
Cash from operations
$1.20
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026